Bayer sharpens its focus as need for pharma to prove value intensifies

In today’s world, cheap insults from people in high places – whether justified or evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair.

Warnings on squeezed budgets from company bosses, evidence of promising pipeline products or figures on the amount that companies invest into research and development (R&D) do not grab the headlines as much as the criticisms or scandals that periodically damage the industry.

"I want people to see the end result, of compounds reaching patients"